All News
From Cytokine Endotypes to Clinical Reality in Still’s Disease
Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy.
Read Article
Increased VTE Risk with Baricitinib
The RA-BRIDGE and RA-BRANCH studies were presented as a late-breaking abstract at EULAR 2026. This was the pooled results from two large FDA post-marketing commitment safety trials — RA-BRIDGE (global) and RA-BRANCH (US-only) — comparing baricitinib at 2 mg and 4 mg daily against TNF inhibitors (etanercept or adalimumab) in RA patients specifically enriched for venous thromboembolic event risk factors.
Read Article
Imaging in SpA: are we seeing a clearer picture?
As EULAR2026 comes to a close, practical learnings take precedence as clinicians head back to their clinics. Among them, the 2026 EULAR Update on Imaging Recommendations in SpA stands out.
Read Article
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).
Read Article
Kyoto U. cohort study of 55 relapsing polychondritis pts (503 Pt-yrs) Rx w/ TNFi, IL-6i or none -- Crude relapse rates were 46.9/100PYs NoBio, 22.4 TNFi, & 12.5 IL-6Ri. Adjusted relapses signif lower w/ TNFi (IRR 0.4) & IL-6Ri (IRR 0.2) vs no biologic. Estimates for hospitalised https://t.co/h6IcVWjqfp
Dr. John Cush RheumNow ( View Tweet)
A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8
Dr. John Cush RheumNow ( View Tweet)
Danish hospital 574 newly diagnosed RA pt, 75% recv glucocorticoids (GC) in 1st yr (55% 1st visit) -- mean dose was 9.3 mg/day, with 46% recv oral tablets & 47% IA steriods injections. 20% had an infection in 1st Yr (RR 1.13; 0.77 to 1.67). Doses declined after 1st visit, but not https://t.co/JcerD61m0t
Dr. John Cush RheumNow ( View Tweet)
MTX: SC vs Oral? Metanalysis of 9 RCTs, 974 RA pts. Compared w/ oral, SC MTX signif. incr odds of ACR20 (RR=1.15), ACR50 (RR=1.14) & reduced GI adverse events (RR=0.58), diarrhea (RR=0.42): BUT no difference in ACR70, DAS28-ESR, bioavailability AUC, or other AE https://t.co/tQeQz7H7do
Dr. John Cush RheumNow ( View Tweet)
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
https://t.co/VLldzkbFU3 https://t.co/5w5wstPawk
Dr. John Cush RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive?
There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions.
https://t.co/FvnqmKSMT4 https://t.co/Qosum9s1UX
Dr. John Cush RheumNow ( View Tweet)
True or False: RA-associated ILD is considered one of the few RA outcomes that has not improved in the biologic era. See if you got it right in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/L7lAA6lwMp
Dr. John Cush RheumNow ( View Tweet)
CAR-T Topic Panel: EULAR 2026
Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T, from emerging data and treatment strategies to real-world challenges in diagnosis and management.
https://t.co/cEOgxNYOXP https://t.co/EUpY9CLL6A
Dr. John Cush RheumNow ( View Tweet)
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush RheumNow ( View Tweet)
Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
Dr. John Cush RheumNow ( View Tweet)
True or False: Current guidelines for peripheral SpA recommend initiating treatment with TNF inhibitors before trying NSAIDs or conventional synthetic DMARDs. See if you got it right in this week's RheumIQ quiz at https://t.co/6uiqJjYUVo https://t.co/9hHFjaGUdt
Dr. John Cush RheumNow ( View Tweet)
“Science is organized knowledge. Wisdom is organized life.” - Immanuel Kant
Dr. John Cush RheumNow ( View Tweet)
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical https://t.co/0rhada36Ji
Dr. John Cush RheumNow ( View Tweet)
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A
Dr. John Cush RheumNow ( View Tweet)
Obinutuzumab drives histologic remission in lupus nephritis
At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/13HY1qIDcj
Dr. John Cush RheumNow ( View Tweet)
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/Qujhl3ktRp
Dr. John Cush RheumNow ( View Tweet)
